Marinus Pharmaceuticals (MRNS) Trading Up 0%

Shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) were up 0% on Thursday . The company traded as high as $4.18 and last traded at $4.15. Approximately 304,783 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 1,200,137 shares. The stock had previously closed at $4.15.

A number of analysts recently weighed in on MRNS shares. Laidlaw started coverage on shares of Marinus Pharmaceuticals in a report on Thursday, December 14th. They issued a “buy” rating and a $18.00 price objective on the stock. BidaskClub raised shares of Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 30th. HC Wainwright started coverage on shares of Marinus Pharmaceuticals in a report on Thursday, February 15th. They issued a “buy” rating and a $33.00 price objective on the stock. Finally, Mizuho started coverage on shares of Marinus Pharmaceuticals in a report on Monday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Marinus Pharmaceuticals has an average rating of “Buy” and an average price target of $18.75.

How to Become a New Pot Stock Millionaire

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Tuesday, March 6th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.07).

In other Marinus Pharmaceuticals news, CEO Christopher Michael Cashman sold 9,566 shares of the firm’s stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $6.28, for a total transaction of $60,074.48. Following the transaction, the chief executive officer now owns 247,903 shares of the company’s stock, valued at approximately $1,556,830.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.60% of the stock is owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in MRNS. Perceptive Advisors LLC acquired a new position in Marinus Pharmaceuticals during the 3rd quarter valued at about $8,527,000. Jennison Associates LLC increased its stake in Marinus Pharmaceuticals by 67.8% during the 4th quarter. Jennison Associates LLC now owns 2,696,553 shares of the biopharmaceutical company’s stock valued at $22,004,000 after buying an additional 1,089,820 shares during the period. Ascend Capital LLC acquired a new position in Marinus Pharmaceuticals during the 4th quarter valued at about $8,264,000. Citadel Advisors LLC increased its stake in Marinus Pharmaceuticals by 1,889.2% during the 4th quarter. Citadel Advisors LLC now owns 1,022,113 shares of the biopharmaceutical company’s stock valued at $8,340,000 after buying an additional 970,730 shares during the period. Finally, 683 Capital Management LLC acquired a new position in Marinus Pharmaceuticals during the 4th quarter valued at about $4,488,000. 63.49% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Marinus Pharmaceuticals (MRNS) Trading Up 0%” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3336875/marinus-pharmaceuticals-mrns-trading-up-0.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: MAM Software Group  Given $8.50 Consensus Target Price by Analysts
Zacks: MAM Software Group Given $8.50 Consensus Target Price by Analysts
Advanced Disposal  Receives Consensus Rating of “Hold” from Analysts
Advanced Disposal Receives Consensus Rating of “Hold” from Analysts
Herc Holdings Inc.  Receives Average Recommendation of “Hold” from Analysts
Herc Holdings Inc. Receives Average Recommendation of “Hold” from Analysts
Freshpet  vs. General Mills  Head to Head Analysis
Freshpet vs. General Mills Head to Head Analysis
Critical Survey: Qurate Retail Group  versus Its Peers
Critical Survey: Qurate Retail Group versus Its Peers
Financial Survey: Telia  versus Its Rivals
Financial Survey: Telia versus Its Rivals


© 2006-2018 Ticker Report. Google+.